{
    "nct_id": "NCT05889845",
    "official_title": "A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Candin for the Treatment of Common Warts (Verruca Vulgaris) in Adolescents and Adults",
    "inclusion_criteria": "* At least 3, but not more than 20 common warts (Verruca vulgaris)\n* Willing to agree to use adequate contraception methods during the study\nHealthy volunteers allowed\nMust have minimum age of 12 Years",
    "exclusion_criteria": "* Systemic or localized diseases, conditions, or medications that could interfere with the assessment of safety or efficacy or that compromise immune function\n* Candin delayed type hypersensitivity reaction test wheal sized < 5 mm or > 25 mm at the Baseline Visit\n* History of keloid formation\n* Prior treatment of common warts with liquid nitrogen, carbon dioxide, electrodesiccation, laser, surgery, salicylic acid, etc., that, in the Investigator's opinion, does not exhibit complete healing from the treatment\n* Treatment with immunotherapy (e.g., diphenylcyclopropenone [DPCP], dinitrochlorobenzene [DNCB], or other), imiquimod, 5-fluorouracil, bleomycin, or podophyllin within 12 weeks of the Baseline Visit or during the study\n* Prior treatment with Candida albicans within 12 weeks of the Baseline Visit or during the study\n* Systemic treatment with an immunosuppressive drug during the study or in the 6 months or 5 half lives prior to the Baseline Visit or during the study (e.g., azathioprine, 6 mercaptopurine, methotrexate, infliximab, adalimumab, etanercept, systemic steroids [topical or inhaled steroids are acceptable]).\n* Use of cantharidin or an investigational agent or device within the 30 days prior to the Baseline Visit or during the study",
    "miscellaneous_criteria": ""
}